论文信息 - Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction - 字舞流文

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

Assent investigators

[1] R. Giugliano,et al. Low-molecular-weight heparins for the treatment of acute coronary syndromes. , 2003, Seminars in vascular medicine.

[2] P. Armstrong,et al. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. , 2001, Circulation.

[3] H. Pereira,et al. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial , 2001, The Lancet.

[4] E. Antman,et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. , 2001, American heart journal.

[5] L. Wallentin,et al. The low‐molecular‐weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study , 2001, Clinical Cardiology.

[6] G Barbash,et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. , 1999, Lancet.

[7] S. Holmberg. Thrombolysis in acute myocardial infarction. , 1992, British journal of hospital medicine.